![](../../files/images/goods/M30568.png)
Dermorphin Analog
CAS No. ——
Dermorphin Analog ( —— )
产品货号. M30568 CAS No. ——
Dermorphin Analog is an analog of Dermorphin. Dermorphin is a natural heptapeptide μ-opioid receptor agonist found in amphibian skin. The dermorphin-derived peptide [Dmt1] dermorphin analog labels m-opioid receptors with high affinity and selectivity in receptor binding assays.
纯度: >98% (HPLC)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
规格 | 价格/人民币 | 库存 | 数量 |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Dermorphin Analog
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Dermorphin Analog is an analog of Dermorphin. Dermorphin is a natural heptapeptide μ-opioid receptor agonist found in amphibian skin. The dermorphin-derived peptide [Dmt1] dermorphin analog labels m-opioid receptors with high affinity and selectivity in receptor binding assays.
-
产品描述Dermorphin Analog is an analog of Dermorphin. Dermorphin is a natural heptapeptide μ-opioid receptor agonist found in amphibian skin. The dermorphin-derived peptide [Dmt1] dermorphin analog labels m-opioid receptors with high affinity and selectivity in receptor binding assays.
-
体外实验——
-
体内实验——
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number——
-
分子量901.43
-
分子式C44H59N11O10
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称Sequence:Tyr-{d-Arg}-Phe-{SAR}-Tyr-Pro-Ser-NH2
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
![](/themes/theme/en/images/ct.png)
![](/themes/theme/en/images/new12.jpg)
![](/themes/theme/en/images/gift.jpg)
![](/themes/theme/en/images/ct2.png)
关联产品
-
Zinc bacitracin
Bacitracin Zinc 是 C55-异戊二烯焦磷酸干扰物的去磷酸化,用于抑制 Tyr 从 Met-脑啡肽上裂解,IC50 为 10 μM。
-
Amifostine
Amifostine 是一种细胞保护佐剂,用于涉及 DNA 结合化疗药物的 Y 化疗和放疗。
-
SJ6986
SJ6986是一种用于研究GSPT1/2体外和体内作用的化学探针。 SJ6986 支持使用多样化的 CRBN 结合物库来靶向不可成药的癌蛋白。